{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"DOR (for participants (pts) with objective response (OR) per IMWG)=time from the first OR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \\>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \\>=0.5 g/dL) (b)Serum M-protein inc \\>=1 g/dL if lowest M component \\>=5 g/dL (c)Urine M-protein (abs inc \\>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \\>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \\>=10%) (ii)appearance of new lesion(s), \\>=50% inc from nadir in SPD of \\>1 lesion, or \\>= 50% inc in longest diameter of a prior lesion \\>1 cm in short axis (iii)\\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.","reportingStatus":"NOT_POSTED","timeFrame":"From treatment initiation till study completion","title":"SSA: Duration of Response (DOR) as Per IMWG Criteria as Determined by Investigator- Phase 1b","type":"SECONDARY"}